CPI: The three biggest barriers to scalable IVD development – and how innovators can overcome them

CPI: The three biggest barriers to scalable IVD development – and how innovators can overcome them

Discover the top barriers in IVD development and how integrated support helps innovators speed time-to-clinic, build confidence, and scale manufacturing.

Forward-thinking in vitro diagnostic (IVD) innovators face growing commercial, clinical, and regulatory pressures. Whether developing molecular diagnostics, digital microfluidic platforms, lateral flow devices, or next-generation point-of-care systems, IVD organisations in the UK, Europe, and the US tend to face the same systemic barriers. These challenges rarely come from a lack of innovation, but rather from gaps between disciplines, regulatory expectations, and the realities of manufacturing at scale.

Read more at CPI